
Annual report 2022
added 08-30-2022
Genetic Technologies Limited Cash Flow 2011-2025 | GENE
Annual Cash Flow Genetic Technologies Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-5.66 M | -6.3 M | -5.71 M | -6.07 M | -5.64 M | -6.85 M | -7.73 M | - | - | - | - | - |
All numbers in AUD currency
Quarterly Cash Flow Genetic Technologies Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|
All numbers in AUD currency
Cash Flow Statement is one of the three key financial reports of the company Genetic Technologies Limited, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Diagnostics research sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
- | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
- | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
$ 17.27 | 1.8 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
$ 15.82 | 0.44 % | $ 170 M | ||
|
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
$ 1.55 | -4.63 % | $ 1.97 M | ||
|
DarioHealth Corp.
DRIO
|
$ 12.14 | 2.1 % | $ 344 M | ||
|
DexCom
DXCM
|
$ 65.83 | -1.69 % | $ 25.4 B | ||
|
Castle Biosciences
CSTL
|
$ 39.06 | 1.11 % | $ 1.08 B | ||
|
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | ||
|
Exact Sciences Corporation
EXAS
|
$ 101.64 | 0.14 % | $ 18.8 B | ||
|
Danaher Corporation
DHR
|
$ 227.72 | 0.54 % | $ 166 B | ||
|
Fulgent Genetics
FLGT
|
$ 27.0 | -0.52 % | $ 816 M | ||
|
Global Cord Blood Corporation
CO
|
- | - | $ 399 M | ||
|
Genetron Holdings Limited
GTH
|
- | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
$ 19.98 | -2.82 % | $ 1.07 B | ||
|
Celcuity
CELC
|
$ 101.67 | -3.4 % | $ 4.01 B | ||
|
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
$ 3.3 | -7.82 % | $ 105 K | ||
|
Co-Diagnostics
CODX
|
$ 0.29 | -14.47 % | $ 8.51 M | ||
|
IQVIA Holdings
IQV
|
$ 222.75 | 0.24 % | $ 40.4 B | ||
|
Guardant Health
GH
|
$ 103.7 | 1.6 % | $ 12.7 B | ||
|
Aspira Women's Health
AWH
|
- | -6.19 % | $ 10.5 M | ||
|
Heska Corporation
HSKA
|
- | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
$ 134.4 | -0.35 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
$ 197.62 | 2.4 % | $ 10.2 B | ||
|
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | ||
|
Mettler-Toledo International
MTD
|
$ 1 410.02 | 1.15 % | $ 29.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
$ 183.96 | 0.79 % | $ 20.4 B | ||
|
NeoGenomics
NEO
|
$ 12.03 | 1.48 % | $ 1.52 B | ||
|
Neogen Corporation
NEOG
|
$ 6.85 | -0.22 % | $ 1.49 B | ||
|
Biodesix
BDSX
|
$ 7.63 | -2.8 % | $ 989 M | ||
|
Myriad Genetics
MYGN
|
$ 7.04 | -2.36 % | $ 638 M | ||
|
Laboratory Corporation of America Holdings
LH
|
$ 262.89 | -0.48 % | $ 22.1 B | ||
|
ICON Public Limited Company
ICLR
|
$ 184.38 | -1.18 % | $ 15.2 B | ||
|
IDEXX Laboratories
IDXX
|
$ 698.77 | -0.77 % | $ 57.6 B | ||
|
Lantheus Holdings
LNTH
|
$ 66.4 | -0.33 % | $ 4.59 B | ||
|
Agilent Technologies
A
|
$ 140.3 | 0.46 % | $ 42.7 B | ||
|
Biomerica
BMRA
|
$ 2.48 | -2.65 % | $ 5.7 M | ||
|
Bioventus
BVS
|
$ 7.49 | -0.86 % | $ 469 M | ||
|
Check-Cap Ltd.
CHEK
|
- | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
$ 2.13 | 0.24 % | $ 540 M | ||
|
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K |